Interferon beta-intranasal - Nastech Pharmaceutical Company

Drug Profile

Interferon beta-intranasal - Nastech Pharmaceutical Company

Latest Information Update: 25 May 2006

Price : $50

At a glance

  • Originator Nastech Pharmaceutical Company
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Multiple sclerosis

Most Recent Events

  • 31 Dec 2014 Biomarkers information updated
  • 25 May 2006 No development reported - Phase-I for Multiple sclerosis in USA (Intranasal)
  • 07 May 2002 Phase-I clinical trials in Multiple sclerosis in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top